IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...

IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...

PHILADELPHIA — Six-month data from the CLASP study showed a transcatheter mitral valve repair system for patients with functional mitral regurgitation conferred acceptable safety and statistically ...

Edwards Lifesciences Corp. ((EW)) announced an update on their ongoing clinical study. Edwards Lifesciences Corp. is currently conducting a pivotal clinical trial titled ‘Edwards PASCAL Transcatheter ...

CHICAGO, IL—In experienced hands, compassionate use of the Pascal transcatheter valve repair system in patients with severe high-risk or inoperable tricuspid regurgitation (TR) can be safe and ...

Progress continues to be made on new transcatheter devices for the treatment of severe mitral and tricuspid regurgitation, investigators reported. Several valve repair and replacement technologies, ...

Please provide your email address to receive an email when new articles are posted on . Edwards Lifesciences announced its precision transcatheter mitral valve repair system for edge-to-edge repair ...

Major adverse events -- cardiovascular death, myocardial infarction, stroke, new need for dialysis, device-related reintervention, severe bleeding, or major access site or vascular complications ...

IRVINE, Calif., Oct. 19, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter ...

The SAPIEN M3 system received CE Mark in April 2025, making it the world’s first approved transfemoral transcatheter mitral ...